期刊
OPHTHALMIC GENETICS
卷 39, 期 5, 页码 560-568出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/13816810.2018.1495745
关键词
Adeno-associated virus; gene therapy; inherited retinal diseases
资金
- National Institute of Health [5P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437]
- National Cancer Institute Core [5P30CA013696]
- Research to Prevent Blindness (RPB) Physician-Scientist Award
- RPB, New York, NY, USA
- Tistou and Charlotte Kerstan Foundation
- Schneeweiss Stem Cell Fund, New York State [C029572]
- Foundation Fighting Blindness New York Regional Research Center Grant [C-NY05-0705-0312]
- Crowley Family Fund
- Gebroe Family Foundation
Hereditary diseases of the retina represent a group of diseases with several heterogeneous mutations that have the common end result of progressive photoreceptor death leading to blindness. Retinal degenerations encompass multifactorial diseases such as age-related macular degeneration, Leber congenital amaurosis, Stargardt disease, and retinitis pigmentosa. Although there is currently no cure for degenerative retinal diseases, ophthalmology has been at the forefront of the development of gene therapy, which offers hope for the treatment of these conditions. This article will explore an overview of the clinical trials of gene supplementation therapy for retinal diseases that are underway or planned for the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据